ProMIS Neurosciences Inc
PMN0.410USD
+0.004+0.86%
Market hours （ET）Quotes delayed by 15 min
13.40MMarket Cap
LossP/E TTM
More Details of ProMIS Neurosciences Inc Company
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
ProMIS Neurosciences Inc Info
Ticker SymbolPMN
Company nameProMIS Neurosciences Inc
IPO dateApr 03, 2017
CEOMr. Neil K. Warma
Number of employees- -
Security typeOrdinary Share
Fiscal year-endApr 03
AddressSuite 200, 1920 Yonge Street
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM4S 3E2
Phone14168476898
Websitehttps://www.promisneurosciences.com/
Ticker SymbolPMN
IPO dateApr 03, 2017
CEOMr. Neil K. Warma
Company Executives of ProMIS Neurosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
130.98K
+0.82%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
101.12K
--
Mr. Eugene W. Williams
Mr. Eugene W. Williams
Chairman of the Board
Chairman of the Board
--
--
Ms. Anne Marie Fields
Ms. Anne Marie Fields
Managing Director
Managing Director
--
--
Ms. Maggie Shafmaster, Ph.D.
Ms. Maggie Shafmaster, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
Independent Director
Independent Director
--
--
Mr. Neil K. Warma
Mr. Neil K. Warma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Larry Altstiel, M.D., Ph.D.
Mr. Larry Altstiel, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
130.98K
+0.82%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
101.12K
--
Mr. Eugene W. Williams
Mr. Eugene W. Williams
Chairman of the Board
Chairman of the Board
--
--
Ms. Anne Marie Fields
Ms. Anne Marie Fields
Managing Director
Managing Director
--
--
Ms. Maggie Shafmaster, Ph.D.
Ms. Maggie Shafmaster, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
1.33K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Oct 17
Updated: Fri, Oct 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ally Bridge Group NY LLC
11.26%
Shaf QIC LLC
9.64%
Jeremy M. Sclar 2012 Irrevocable Family Trust
6.90%
Jeremy M. Sclar 2012 Irrevocable Family Trust
6.90%
Great Point Partners, LLC
4.92%
Other
60.40%
Shareholders
Shareholders
Proportion
Ally Bridge Group NY LLC
11.26%
Shaf QIC LLC
9.64%
Jeremy M. Sclar 2012 Irrevocable Family Trust
6.90%
Jeremy M. Sclar 2012 Irrevocable Family Trust
6.90%
Great Point Partners, LLC
4.92%
Other
60.40%
Shareholder Types
Shareholders
Proportion
Corporation
23.20%
Hedge Fund
20.81%
Individual Investor
8.42%
Investment Advisor
0.60%
Bank and Trust
0.05%
Family Office
0.05%
Research Firm
0.03%
Investment Advisor/Hedge Fund
0.02%
Other
46.82%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
33
11.58M
21.51%
-2.51M
2025Q2
46
17.85M
59.19%
-81.84K
2025Q1
45
18.32M
56.87%
+570.44K
2024Q4
46
18.77M
57.42%
+658.84K
2024Q3
49
19.14M
58.55%
+4.98M
2024Q2
41
6.77M
35.75%
-201.91K
2024Q1
40
6.90M
39.50%
+44.33K
2023Q4
36
6.86M
39.39%
+553.48K
2023Q3
36
6.32M
55.88%
+2.93M
2023Q2
30
1.47M
19.09%
+793.97K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ally Bridge Group NY LLC
6.06M
11.26%
--
--
Sep 17, 2025
Shaf QIC LLC
5.18M
9.64%
--
--
Sep 17, 2025
Jeremy M. Sclar 2012 Irrevocable Family Trust
3.71M
6.9%
+2.09M
+129.40%
Jul 25, 2025
Great Point Partners, LLC
2.65M
4.92%
--
--
Jun 30, 2025
Title 19 ProMIS
2.44M
4.53%
-584.28K
-19.35%
Jul 25, 2025
Armistice Capital LLC
2.14M
3.97%
-196.93K
-8.43%
Jun 30, 2025
Crocker Mountain LLC
4.93M
9.16%
+3.78M
+326.67%
Sep 17, 2025
Sphera Funds Management Ltd.
1.90M
3.53%
-30.00K
-1.55%
Jun 30, 2025
Shafmaster (Madge K.)
200.00K
0.37%
--
--
Sep 17, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
